Table 2.
Clinicopathological data and p16 expression in gastrointestinal stromal tumors
| Case | Sex | Age (yr) | Risk1 | Site | OS (mo) | 1751 | 1846 | 942 | 1748 | p16 expression |
| 1 | Male | 41 | Low | SI | Alive (50) | 2 | 2 | 2 | 3 | N |
| 2 | Male | 73 | Low | S | Alive (47) | 3 | 2 | 4 | 4 | N |
| 3 | Male | 33 | Very low | SI | Alive (21) | 4 | 3 | 2 | 4 | N |
| 4 | Female | 66 | Low | S | Alive (18) | 4 | 4 | 3 | 3 | P |
| 5 | Female | 71 | Low | SI | Alive (17) | 4 | 4 | 4 | 4 | P |
| 6 | Male | 46 | Low | SI | Alive (15) | 4 | 4 | 4 | 3 | P |
| 7 | Female | 59 | Low | SI | Alive (5) | 3 | 4 | 4 | 3 | P |
| 8 | Female | 45 | Low | SI | Alive (13) | 4 | 3 | 3 | 4 | P |
| 9 | Male | 65 | Low | SI | Alive (11) | 3 | 3 | 3 | 4 | P |
| 10 | Male | 66 | Low | S | Alive (11) | 4 | 4 | 4 | 4 | P |
| 11 | Male | 55 | Low | S | Alive (5) | 3 | 2 | 2 | 4 | N |
| 12 | Male | 72 | Low | SI | Alive (102) | 2 | 3 | 4 | 2 | P |
| 13 | Female | 54 | Low | S | Alive (50) | 3 | 3 | 3 | 3 | P |
| 14 | Male | 56 | Low | S | NA | 4 | 4 | 4 | 4 | P |
| 15 | Female | 60 | Low | S | NA | 3 | 3 | 3 | 3 | P |
| 16 | Male | 70 | Very low | S | Alive (45) | 3 | 3 | 4 | 4 | P |
| 17 | Female | 75 | Low | S | Alive (18) | 3 | 3 | 4 | 3 | P |
| 18 | Male | 70 | Intermediate | S | Alive (100) | 4 | 2 | 2 | 3 | N |
| 19 | Female | 50 | Intermediate | SI | Alive (81) | 4 | 4 | 4 | 4 | P |
| 20 | Female | 70 | Intermediate | S | Alive (88) | 4 | 4 | 2 | 2 | N |
| 21 | Male | 72 | Intermediate | SI | Alive (78) | 2 | 4 | 4 | 3 | P |
| 22 | Male | 56 | Intermediate | SI | Dead (60) | 3 | 2 | 2 | 3 | P |
| 23 | Male | 47 | Intermediate | S | Alive (53) | 2 | 3 | 4 | 4 | P |
| 24 | Male | 50 | Intermediate | M | Dead (27) | 3 | 3 | 4 | 4 | P |
| 25 | Female | 73 | Intermediate | S | Alive (21) | 3 | 2 | 2 | 4 | N |
| 26 | Male | 79 | Intermediate | S | Alive (16) | 4 | 3 | 4 | 4 | P |
| 27 | Male | 63 | Intermediate | S | Alive (12) | 3 | 4 | 4 | 4 | P |
| 28 | Male | 68 | Intermediate | S | Alive (12) | 3 | 2 | 4 | 4 | P |
| 29 | Female | 56 | Intermediate | S | Alive (11) | 3 | 4 | 4 | 3 | P |
| 30 | Female | 57 | Intermediate | SI | Alive (9) | 4 | 4 | 3 | 4 | P |
| 31 | Male | 59 | Intermediate | S | Alive (35) | 3 | 4 | 3 | 2 | N |
| 32 | Female | 29 | High | SI | Dead (38) | 3 | 4 | 4 | 2 | N |
| 33 | Female | 77 | High | S | Dead (35) | 4 | 4 | 2 | 4 | N |
| 34 | Male | 64 | High | M | Alive (71) | 2 | 4 | 2 | 3 | N |
| 35 | Male | 47 | High | S | Dead (56) | 2 | 4 | 2 | 4 | N |
| 36 | Female | 50 | High | S | Alive (62) | 3 | 2 | 4 | 2 | N |
| 37 | Female | 36 | High | SI | Dead (11) | 2 | 4 | 4 | 4 | N |
| 38 | Female | 62 | High | S | Alive (55) | 4 | 2 | 3 | 2 | P |
| 39 | Male | 60 | High | S | Alive (54) | 3 | 4 | 3 | 4 | P |
| 40 | Female | 61 | High | S | Alive (63) | 2 | 3 | 3 | 4 | N |
| 41 | Male | 50 | High | S | Alive (51) | 3 | 3 | 3 | 2 | P |
| 42 | Male | 75 | High | S | Dead (18) | 2 | 4 | 2 | 3 | N |
| 43 | Male | 58 | High | S | Alive (46) | 3 | 3 | 3 | 4 | P |
| 44 | Male | 52 | High | S | Alive (31) | 4 | 3 | 2 | 3 | N |
| 45 | Male | 56 | High | SI | Alive (31) | 3 | 2 | 4 | 3 | P |
| 46 | Male | 57 | High | SI | Alive (19) | 2 | 3 | 2 | 4 | P |
| 47 | Male | 67 | High | M | Alive (18) | 3 | 2 | 3 | 2 | P |
| 48 | Female | 47 | High | SI | Dead (5) | 4 | 3 | 2 | 3 | N |
| 49 | Female | 80 | High | SI | Alive (12) | 3 | 3 | 2 | 4 | N |
| 50 | Female | 48 | High | S | Alive (12) | 3 | 3 | 2 | 3 | P |
| 51 | Male | 44 | High | S | Dead (86) | 4 | 2 | 4 | 3 | N |
According to the consensus approach by Fletcher et al[4];
Indicates loss of heterozygosity (LOH);
Uninformative (homozygosity);
Indicates no LOH. S: Stomach; SI: Small intestine; M: Mesentery; NA: Not available; OS: Overall survival; N: Negative expression; P: Positive expression.